Busulphan
Covid19
Uppsala UniversityDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Covid19 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
cc-220 Nguyen Thi Trieu, MD | Phase 4 | BB |
Genotropin ClinAmygate | Phase 4 | BB |
Niclosamide Cambridge University Hospitals NHS Foundation Trust | Phase 2/3 | B |
CICLESONIDE Cambridge University Hospitals NHS Foundation Trust | Phase 2/3 | B |
Gam-Covid-Vac Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Phase 3 | B |
View all 14 →
Same molecule, other indications
Busulphan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →